DOI QR코드

DOI QR Code

Successful remission with L-CHOP for primary mediastinal B-cell lymphoma in a young Maltese dog

  • Chang, Seiyoung (Veterinary Medical Center and College of Veterinary Medicine, Chungbuk National University) ;
  • Kim, Hakhyun (Veterinary Medical Center and College of Veterinary Medicine, Chungbuk National University) ;
  • Kang, Ji-Houn (Veterinary Medical Center and College of Veterinary Medicine, Chungbuk National University) ;
  • Kang, Byeong-Teck (Veterinary Medical Center and College of Veterinary Medicine, Chungbuk National University) ;
  • Chang, Dongwoo (Veterinary Medical Center and College of Veterinary Medicine, Chungbuk National University) ;
  • Na, Ki-Jeong (Veterinary Medical Center and College of Veterinary Medicine, Chungbuk National University) ;
  • Yang, Mhan-Pyo (Veterinary Medical Center and College of Veterinary Medicine, Chungbuk National University)
  • Received : 2018.10.08
  • Accepted : 2018.12.16
  • Published : 2018.12.31

Abstract

A one-year-old, intact female, Maltese dog was presented with a history of anorexia and regurgitation. Thoracic radiographs and ultrasonography scans suggested an abnormal mass in the cranial mediastinal region, and computed tomography confirmed the origin of this mass. Ultrasound-guided fine needle aspiration cytology showed the presence of intermediate to large lymphoid cells showing mitotic figures. B-cell lymphoma was confirmed by the result of a polymerase chain reaction assay for antigen receptor rearrangement, therefore the patient was diagnosed with primary mediastinal large B-cell lymphoma (PMBL). The patient underwent L-CHOP (L-asparaginase, cyclophosphamide, doxorubicin, vincristine, prednisolone)-based chemotherapy, and showed complete tumoral remission from the beginning of chemotherapy. Seventytwo weeks after the completion of chemotherapy, the patient is still alive without any evidence of metastasis or relapse. A standardized treatment protocol has yet to be established for primary mediastinal lymphoma in dogs. This case report describes the complete remission of PMBL by an L-CHOP-based chemotherapy protocol in a young Maltese. Clinicians should consider that L-CHOP based chemotherapy may be useful against PMBL in dogs.

Keywords

Acknowledgement

Supported by : National Research Foundation of Korea (NRF)

References

  1. Dorn CR, Taylor DON, Schneider R, Hibbard HH, Klauber MR. Survey of animal neoplasms in Alameda and Contra Costa Counties, California. II. Cancer morbidity in dogs and cats from Alameda County. J Natl Cancer Inst 1968;40:307-318.
  2. Merlo DF, Rossi L, Pellegrino C, Ceppi M, Cardellino U, Capurro C, Ratto A, Sambucco PL, Sestito V, Tanara G, Bocchini V. Cancer incidence in pet dogs: findings of the animal tumor registry of Genoa, Italy. J Vet Intern Med 2008;22:976-984. https://doi.org/10.1111/j.1939-1676.2008.0133.x
  3. Villamil JA, Henry CJ, Hahn AW, Bryan JN, Tyler JW, Caldwell CW. Hormonal and sex impact on the epidemiology of canine lymphoma. J Cancer Epidemiol 2009;591753.
  4. Martelli M, Di Rocco A, Russo E, Perrone S, Foa R. Primary mediastinal lymphoma: diagnosis and treatment options. Expert Rev Hematol 2015;8:173-186. https://doi.org/10.1586/17474086.2015.994604
  5. Bassan R, Maino E, Cortelazzo S. Lymphoblastic lymphoma: an updated review on biology, diagnosis, and treatment. Eur J Haematol 2016;96:447-460. https://doi.org/10.1111/ejh.12722
  6. Moore EL, Vernau W, Rebhun RB, Skorupski KA, Burton JH. Patient characteristics, prognostic factors and outcome of dogs with high-grade primary mediastinal lymphoma. Vet Comp Oncol 2018;16:E45-E51. https://doi.org/10.1111/vco.12331
  7. Chun R, Garrett LD, Vail DM. Evaluation of a high-dose chemotherapy protocol with no maintenance therapy for dogs with lymphoma. J Vet Intern Med 2000;14:120-124. https://doi.org/10.1111/j.1939-1676.2000.tb02224.x
  8. Rebhun RB, Kent MS, Borrofka SAEB, Frazier S, Skorupski K, Rodriguez CO. CHOP chemotherapy for the treatment of canine multicentric T-cell lymphoma. Vet Comp Oncol 2011;9:38-44. https://doi.org/10.1111/j.1476-5829.2010.00230.x
  9. Curran K, Thamm DH. Retrospective analysis for treatment of naive canine multicentric lymphoma with a 15-week, maintenance-free CHOP protocol. Vet Comp Oncol 2016;14:147-155.
  10. Dunleavy K, Pittaluga S, Maeda LS, Advani R, Chen CC, Hessler J, Steinberg SM, Grant C, Wright G, Varma G, Staudt LM, Jaffe ES, Wilson WH. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med 2013;368:1408-1416. https://doi.org/10.1056/NEJMoa1214561
  11. Rieger M, Osterborg A, Pettengell R, White D, Gill D, Walewski J, Kuhnt E, Loeffler M, Pfreundschuh M, Ho AD. Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study. Ann Oncol 2011;22:664-670. https://doi.org/10.1093/annonc/mdq418
  12. Rosenberg MP, Matus RE, Patnaik AK. Prognostic factors in dogs with lymphoma and associated hypercalcemia. J Vet Intern Med 1991;5:268-271. https://doi.org/10.1111/j.1939-1676.1991.tb03133.x
  13. Avery PR, Burton J, Bromberek JL, Seelig DM, Elmslie R, Correa S, Ehrhart EJ, Morley PS, Avery AC. Flow cytometric characterization and clinical outcome of CD4+ T-cell lymphoma in dogs: 67 cases. J Vet Intern Med 2014;28:538-546. https://doi.org/10.1111/jvim.12304
  14. Garrett LD, Thamm DH, Chun R, Dudley R, Vali DM. Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma. J Vet Intern Med 2002;16:704-709. https://doi.org/10.1111/j.1939-1676.2002.tb02411.x
  15. Piek CJ, Rutteman GR, Teske E. Evaluation of the results of a L-asparaginase-based continuous chemotherapy protocol versus a short doxorubicin-based induction chemotherapy protocol in dogs with malignant lymphoma. Vet Q 1999;21:44-49. https://doi.org/10.1080/01652176.1999.9694990
  16. Cazals-Hatem D, Lepage E, Brice P, Ferrant A, d'Agay MF, Baumelou E, Briere J, Blanc M, Gaulard P, Biron P, Schlaifer D, Diebold J, Audouin J. Primary mediastinal large B-cell lymphoma. A clinicopathologic study of 141 cases compared with 916 nonmediastinal large B-cell lymphomas, a GELA ("Groupe d'Etude des Lymphomes de l'Adulte") study. Am J Surg Pathol 1996;20:877-888. https://doi.org/10.1097/00000478-199607000-00012
  17. Zhu YJ, Huang JJ, Xia Y, Zhao W, Jiang WQ, Lin TY, Huang HQ, Li ZM. Primary mediastinal large B-cell lymphoma (PMLBCL) in Chinese patients: clinical characteristics and prognostic factors. Int J Hematol 2011;94:178-184. https://doi.org/10.1007/s12185-011-0898-4
  18. Teske E, van Heerde P, Rutteman GR, Kurzman ID, Moore PF, and MacEwen EG. Prognostic factors for treatment of malignant lymphoma in dogs. J Am Vet Med Assoc 1994;205:1722-1728.
  19. Ponce F, Magnol JP, Ledieu D, Marchal T, Turinelli V, Chalvet-Monfray K, Fournel-Fleury C. Prognostic significance of morphological subtypes in canine malignant lymphomas during chemotherapy. Vet J 2004;167:158-166. https://doi.org/10.1016/j.tvjl.2003.10.009
  20. Goldschmidt N, Kleinstern G, Orevi M, Paltiel O, Ben-Yehuda D, Gural A, Libster D, Lavie D, Gatt ME. Favorable outcome of primary mediastinal large B-cell lymphoma patients treated with sequential RCHOPRICE regimen without radiotherapy. Cancer Chemother Pharmacol 2016;77:1053-1060. https://doi.org/10.1007/s00280-016-3024-8